ArticleScientific reports2025
Establishing molecular biomarkers for efficient demarcation of tumor and non-tumor tissue in oral squamous cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC), which accounts for 90% of head and neck cancers (HNSC), is a prevalent cancer, especially in India, where it ranks among the top three cancers. Despite treatment advancements, OSCC incidence is rising, and recurrence remains a major concern. To improve patient prognosis, effective biomarkers for tumor demarcation are crucial. RNA isolation, library preparation, and RNA sequencing were performed on tumor and adjacent normal oral tissue samples. Transcriptomic analysis identified differentially expressed genes (DEGs) between tumor and normal tissues, which may serve as potential biomarkers. These findings were subsequently validated using RT-qPCR. The analysis revealed 704 upregulated and 1540 downregulated genes. Among these from the top 100 upregulated and downregulated genes, 15 and 9 genes respectively were also reported in the HNSC database of TCGA (The Cancer Genome Atlas). To identify potential biomarkers, the study evaluated multiple factors, including log2 fold change, average RPKM, ROC curve analysis, protein-protein interaction (PPI) network analysis and gene ontology (GO) analysis. The differential expression across various cancer stages and individual sample comparisons were also assessed. The upregulated genes MMP1, MMP10, MMP13, MMP3, ADAM12, IL24, and ISG15 demonstrated potential as biomarkers, with the highest log2 fold change, average RPKM, and AUC values. These significant genes could be valuable biomarkers for efficient demarcation between tumor and non-tumor tissues in oral cancer. This could lead to improved margin clearance, addressing concerns related to high recurrence rate of OSCC and ultimately enhance patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.